Objective
to investigate the clinical outcomes of the use of apixaban versus standard of care after successful TAVI. Standard of care: stratum I: Vit. K antagonists entire study and stratum 2: pts with no indication for oral anticoagulation were given antiplatelet treatment: aspirin and/or clopidogrel
Study
investigator-initiated open-label superiority multicentre randomised trial
Population
patients with successful TAVI
Endpoints
composite of death, MI, stroke, TIA, systemic embolism, intracardiac or bioprothesis thrombosis, deep vein thrombosis, pulmonary embolism, life-threatening, disabling or major bleeding over 1-year follow-up. Safety endpoint: major, disabling or life-threatening bleeding
Conclusion
Apixaban was not superior to standard of care after successful TAVI over a period of 1 year
Collet et al. European Heart Journal. 2022;43:2783-97
